This section hosts guidelines, manuals and toolkits to strengthen public health practice.
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing the risk of HIV acquisition.
This guideline provides implementation considerations to support Member States, program managers, policymakers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programs for CAB-LA. It also outlines critical research gaps for CAB-LA.
To read the guideline, please click the linked file.